AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER

ARFID

OVERVIEW OF CURRENT RESEARCH












Dr Hannah Kennedy, Department of Psychological Medicine, University of Otago -Christchurch

Jomine Ayers - Mother of two boys with ARFID

WHO AM I?

PostDoc (cancer genetics)











WHAT IS ARFID?

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS (DSM-5) DEFINITION:

An eating or food disturbance as manifested by persistant failure to meet appropriate nutritional and/or energy needs associated with one or more of the following:

- Significant weight loss (or faltering growth)
- Significant nutritional deficiency
- Dependance on oral supplements or tube feeding
- Marked interference with psychosocial functioning











WHAT IS ARFID NOT?



- No body weight or shape concerns (occurs during Anorexia nervosa or Bulimia nervosa)
- Not better explained by another current condition.
- Cultural practice or lack of available food
























ARFID SUBTYPES

- Three proposed subtypes
- Not mutually exclusive

AVERSIVE

AVOIDANT









- Commonly acute onset triggered by trauma
- Fear of:
 - -choking
 - -vomiting
 - -pain
 - -contamination
- Most frequent adult presentation

- Low appetite
- Lack of interest in food
- No enjoyment from eating
- Feels full quickly
- Often present from early life

- Extreme 'picky eating'
- Limited range of accepted foods
- Sensory sensitivity
- Often comorbid ASD
- Early onset is common












WHAT DO WE KNOW?















Prevalence

Significant variability in prevalence estimates:

- General population: <1%-5.5% (all studies screened for ARFID in a different manner)
- Adults 0.3% (n= ~3000 South Australians) Hay et al., 2017
- Children 2.0% (31%F) (n =>33 000 twins from Swedish longitudinal cohort) Dinkler et al., 2023
- Equal prevalence in males and females in general population.

Children ~2% Adults ~0.3%













Onset

Heritability



Can be at any age, but childhood onset is common, and younger than in other EDs:

- Median age = 6y ARFID vs 12y Anorexia nervosa
 (AN) Thomas et al., 2017
- Median age = 8.7y ARFID Hameed et al., 2018
- Adult-onset ARFID Aversive subtype is most frequent, where a traumatic event often precipitates food avoidance.

Genetic heritability = the degree to which genetic factors play a role in the development or susceptibility to ARFID.

- "Genetics loads the gun, while environment pulls the trigger"
- First twin study of ARFID (Feb 2023)

JAMA Psychiatry | Original Investigation

Etiology of the Broad Avoidant Restrictive Food Intake Disorder Phenotype in Swedish Twins Aged 6 to 12 Years

Lisa Dinkler, PhD; Marie-Louis Wronski, MSc; Paul Lichtenstein, PhD; Sebastian Lundström, PhD; Henrik Larsson, PhD; Nadia Micali, PhD; Mark J. Taylor, PhD; Cynthia M. Bulik, PhD

- Heritability = 70-85% genetic factors
- More heritable than AN (48-74%) and closer to ASD (79-84%)!













Condition overlap

Health consequences



Neurodevelopmental disorders are more common in individuals with ARFID

- Children with significant early neurodevelopmental challenges - 3x increased risk of developing ARFID (Dinkler et al., 2022)
- Specific areas predictive of ARFID were challenges in general development, communication/language, attention/concentration, social interaction, and sleep.
- Anxiety, ASD, ADHD, OCD, & mood disorders also common.

Severe medical consequences secondary to malnutrition and/or low weight:

- Cardiovascular complications
- Osteoporosis and bone fractures
- Organ damage




subacute combined degeneration of spinal cord - secondary to B12 deficiency



Optic neuropathy/retinopathy
















WHAT RESEARCH HAS BEEN DONE IN AUSTRALASIA?



- Systematic review of all published literature from NZ and Australia since 2013 that relates to ARFID
- ~160 papers ---> 30 relevant studies ---> data extraction
- Who? What? Where? How?










Data summary



- Studies grouped by sample type (Population, health professionals, caregivers or clinical).
- Represented here seperated by average age and gender, size of bubble reflects sample number.









Data summary



Have:

- Muliple isolated case reports (1 series)
- Gender balance
- Some population data in adulthood

Missing:

- Larger-scale patient samples in both childhood and adulthood
- Population studies in children that give ARFID prevalence data
- Studies of caregivers










Data summary



"When presented with a typical case vignette suggestive of ARFID, the majority of NZ health professional respondents did not label the case as ARFID in a multichoice answer, and 89.7% said there was "no consensus" on a label"

- Wide range of health specialties may be expected to recognise and treat ARFID.
- NZ (and international!) data suggests confidence is lacking for many.

Five years of Avoidant/Restrictive Food Intake Disorder: no consensus of understanding among health professionals in New Zealand

Bianca N. Jackson, Léa A. T. Turner, Georgina L. Kevany & Suzanne C. Purdy

To cite this article: Bianca N. Jackson, Léa A. T. Turner, Georgina L. Kevany & Suzanne C. Purdy (2021); Five years of Avoidant/Restrictive Food Intake Disorder: no consensus of understanding among health professionals in New Zealand, Speech, Language and Hearing, DOI: 10.1080/2050571X.2021.1926620

To link to this article: https://doi.org/10.1080/2050571X.2021.1926620

"Experience and confidence in diagnosing and treating ARFID are generally low in Swedish clinicians, and many individuals with ARFID do not receive treatment."













Recommendations

- Continuing education of heath professionals
- Move towards standard screening and assessment instruments
- Increased studies on clinical samples What are the characteristics of ARFID in Australasia?
- Large-scale studies in the general population for more accurate prevalence estimates - Adults AND Children
- Further research to understand ARFID in non-European populations
- Treatment trials -Effectiveness of treatment interventions
- Inclusion of individuals with lived experience in co-desgining research













EATING

- > chews and swallows whole bolus independently
- chews, swallows whole bolus with drink
- chews, swallows some and spits some
- bites, chews "x" times & spits out
- bites pieces, holds in mouth for "x" seconds & spits out
- > bites off piece & spits out immediately
- > full tongue lick
- > licks lips or teeth

TASTE

- tip of tongue, top of tongue
- > teeth
- > lips
- nose, underneath nose
- > chin, cheek
- > top of head
- > chest, neck
- arm, shoulder
- whole hand
- fingertips, fingerpads
- one finger tip

TOUCH

- leans down or picks up to smell
- odor in child's forward space
- odor at table
- odor in room

SMELLS

- uses utensils or container to serve self onto own plate/space
- uses utensils or a container to stir or pour food/drink outside of own space
- > uses utensils or a container to stir or pour food/drink for others
- assists in preparation/set up with food

INTERACTS WITH

- looks at food when directly in child's space
- being at the table with the food just outside of child's space
- being at the table with the food ½ way across the table
- being at the table with the food on the other side of the table
- being in the same room

STEPS TO EATING

TOLERATES

Dr Kay A Toomey, PhD Toomey@starcenter.us Copyright 200























NZ ARFID SURVEY

Understanding the research priorities of those most affected by ARFID

- ~500 respondents completed an online survey
- Demographic and ARFID symptomology questions
- Asked to rate importance of 34 ARFID research areas
- Suggest any additional priorities
- Only 23% have a clinical ARFID diagnosis (self-reported)
- Majority believe they have ARFID but have never recieved a dx











TOP PRIORITIES - INDIVIDUALS WITH ARFID

- Impacts of other co-existing conditions (eg. anxiety, ASD, ADHD)
- Onset of ARFID (how/when/why)
- Understanding ARFID across the lifespan (childhood-adulthood)
- Exploring combined mental health prevention programs
- Availability and accessibility of evidence-based treatment guidelines













TOP PRIORITIES - PARENTS AND CAREGIVERS

- Increasing recognition of ARFID by health professionals
- Interventions (enchance existing, develop new)
- Impacts of other co-existing conditions (eg. anxiety, ASD, ADHD)
- Availability and accessibility of evidence-based treatment guidelines













WHERE TO NOW?

OUR ARFID PRIORITIES

- Elevate the profile of ARFID for health professionals that may encounter it
- Encourage a community of researchers, clinicians, and individuals with lived experience of ARFID in NZ to engage in planning future research
- Conduct first large-scale study of ARFID in NZ
- --> observable behaviour and traits (phenotype) data
- --> genetic sample
- Understand the drivers of ARFID (Genetic background + environmental impacts)
- Long term aim of better treatment and prevention options!









THANK YOU!

hannah.kennedy@otago.ac.nz



















